Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2

British Journal of Cancer

Volumn 109, Issue 9, 2013, Pages 2389-2395

  Harada, K ^a   Miyake, H ^a   Kumano, M ^a   Fujisawa, M ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

mTORC1; mTORC2; renal cell carcinoma; temsirolimus

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; BETA ACTIN; CLUSTERIN; EVEROLIMUS; KU 0063794; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44; S6 KINASE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN CELL; IC 50; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84887022988     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.602     Document Type: Article

References (28)

1. Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A (2007) Present strategies in the treatment of metastatic renal cell carcinoma: An update on molecular targeting agents. BJU Int 99: 274-280.
2. Carew JS, Kelly KR, Nawrocki ST (2011) Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol 6: 17-27.
3. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
4. Chen XG, Liu F, Song XF, Wang ZH, Dong ZQ, Hu ZQ, Lan RZ, Guan W, Zhou TG, Xu XM, Lei H, Ye ZQ, Peng EJ, Du LH, Zhuang QY (2010) Rapamycin regulates Akt and ERK phosphorylation through mTORC11 and mTORC2 signaling pathways. Mol Carcinog 49: 603-610.
5. Darwiche N, Sinjab A, Abou-Lteif G, Chedid MB, Hermine O, Dbaibo G, Bazarbachi A (2011) Inhibition of mammalian target of rapamycin signaling by everolimus induces senescence in adult T-cell leukemia/ lymphoma and apoptosis in peripheral T-cell lymphomas. Int J Cancer 129: 993-1004.
6. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120: 2858-2866.
7. Foster KG, Fingar DC (2010) Mammalian target of rapamycin (mTOR): Conducting the cellular signaling symphony. J Biol Chem 285: 14071-14077.
8. González Larriba JL, Espinosa E, García Carbonero I, García-Donas J, López M, Meana A, Puente J, Bellmunt J (2012) Sequential therapy in metastatic renal cell carcinoma: Pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. Cancer Metastasis Rev 31(Suppl 1): S11-S17.
9. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118: 2609-2619.
10. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
11. Kumano M, Miyake H, Kurahashi T, Yamanaka K, Fujisawa M (2008) Enhanced progression of human prostate cancer PC3 cells induced by the microenvironment of the seminal vesicle. Br J Cancer 98: 356-362.
12. Lane BR, Rini BI, Novick AC, Campbell SC (2007) Targeted molecular therapy for renal cell carcinoma. Urology 69: 3-10.
13. Le Tourneau C, Faivre S, Serova M, Raymond E (2008) mTORC1 inhibitors: Is temsirolimus in renal cancer telling us how they really work?. Br J Cancer 99: 1197-1203.
14. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594-601.
15. Menon S, Manning BD (2008) Common corruption of the mTOR signaling network in human tumors. Oncogene 27(Suppl 2): S43-S51.
16. Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M (2009) Clinical outcome of combined immunotherapy with interferon-Alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urol Oncol 27: 598-603.
17. Morgillo F, Bareschino MA, Bianco R, Tortora G, Ciardiello F (2007) Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 75: 788-799.
18. Muramaki M, So A, Hayashi N, Sowery R, Miyake H, Fujisawa M, Gleave ME (2009) Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-Apoptotic gene, clusterin. BJU Int 103: 384-390.
19. Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K (2009) Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res 15: 907-913.
20. Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A, Yamanaka K, Ono M, Nakagawa K (2012) Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin. Mol Cancer Ther 11: 204-213.
21. Parton M, Gore M, Eisen T (2006) Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 24: 5584-5592.
22. Rini BI, Atkins MB (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10: 992-1000.
23. Rini BI, Rathmell WK, Godley P (2008) Renal cell carcinoma. Curr Opin Oncol 20: 300-306.
24. Sakai I, Miyake H, Fujisawa M (2013) Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation. BJU Int 112(2): E211-E220.
25. Singh BN, Kumar D, Shankar S, Srivastava RK (2012) Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/ Akt/mTOR pathway in human pancreatic cancer stem cells. Biochem Pharmacol 84: 1154-1163.
26. Sparks CA, Guertin DA (2010) Targeting mTOR: Prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 29: 3733-3744.
27. Terakawa T, Miyake H, Furukawa J, Ettinger SL, Gleave ME, Fujisawa M (2009) Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. Br J Cancer 101: 1731-1739.
28. Voss MH, Molina AM, Motzer RJ (2011) mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 25: 835-852.